• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    10/15/24 9:40:22 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email
    SC 13D/A 1 ff3996442_13da4-tangoboxcap.htm



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (RULE 13D - 101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND
    AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
    (Amendment No. 4)*
    Tango Therapeutics, Inc.
    (Name of Issuer)
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

    87583X109
    (CUSIP Number)


    Josh La Grange
    Fried, Frank, Harris, Shriver & Jacobson LLP
    801 17th Street, NW, Washington, DC 20006
    202-639-7497
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)


    October 10, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Capital Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     
    6,988,450
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     
    6,988,450
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    6,988,450
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    6.5%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     OO
     
     
     
     





    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     0
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     OO
     
     
     
     





    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    MVA Investors, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    108,793
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    108,793
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    108,793
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    0.1%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     OO
     
     
     
     





    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     
    32,500
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    8,307,435
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     
    32,500
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    8,307,435
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    8,339,935
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    7.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     




    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Capital Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    8,198,642
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    8,198,642
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    8,198,642
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    7.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    OO, IA
     
     
     
     






    With respect to BCTG Holdings, LLC (“BCTG Holdings”), MVA Investors, LLC (“MVA Investors”), Aaron I. Davis and Boxer Capital, LLC (“Boxer Capital”), this amendment (this “Amendment No. 4”) further amends and supplements the statement on Schedule 13D filed on August 20, 2021 (the “Original Filing”) by BCTG Holdings, Boxer Capital, Boxer Asset Management Inc. (“Boxer Management”), MVA Investors, Mr. Davis and Joe Lewis with respect to the Common Stock, par value $0.001 (the “Common Stock”) of Tango Therapeutics, Inc. (the “Issuer”), as previously amended and filed on January 4, 2022 (“Amendment No. 1”), August 16, 2023 (“Amendment No. 2”) and October 18, 2023 (“Amendment No. 3”). Amendment No. 1 was an original filing for Braslyn Ltd. (“Braslyn”). On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management, LLC (“BCM”), a registered investment advisor controlled by Mr. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. To the extent applicable, the Original Filing, as previously and hereby amended, is hereby adopted by BCM as its original filing on Schedule 13D regarding the Issuer. Capitalized terms used herein but not defined herein shall have the respective meanings defined in the Original Filing, as previously amended. The Original Filing, as previously amended, is further amended hereby only as specifically set forth herein, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Filing, as previously amended, such incorporation by reference is also amended hereby. Boxer Capital reports herein that it has ceased to beneficially own more than 5% of the outstanding shares of Common Stock. On or about the day of this filing, Boxer Management, Braslyn and Mr. Lewis are independently amending the Original Filing with respect to themselves; see that filing for any required information pertaining to any of them.

    Item 2.
    Identity and Background.

    Item 2 is hereby amended and restated to read as follows:
    This Schedule 13D is jointly filed by BCTG Holdings, Boxer Capital, MVA Investors, Mr. Davis and BCM (collectively, the "Reporting Persons").
    BCTG Holdings, a limited liability company organized under the laws of Delaware, is primarily involved in the business of investment in securities. BCTG Holdings is majority-owned by Boxer Capital and Mr. Davis is a manager of BCTG Holdings. The board of managers of BCTG Holdings has voting and dispositive power over securities owned by BCTG Holdings.
    Boxer Capital is a limited liability company organized under the laws of Delaware. BCM, a limited liability company organized under the laws of Delaware, is a registered investment advisor, providing investment management services to Boxer Capital. Each of Boxer Capital and BCM is primarily engaged in the business of investing in securities.
    MVA Investors, a limited liability company organized under the laws of Delaware, is the independent, personal investment vehicle of certain employees of BCM. MVA Investors is primarily engaged in the business of investment in securities.
    Mr. Davis, a citizen of the United States and the Chief Executive Officer of Boxer Capital and is a member of and has voting and dispositive power over securities held by MVA Investors and BCM. With his immediate family, Mr. Davis indirectly owns the membership interests in BCM.
    By virtue of these relationships, BCTG Holdings, Boxer Capital, MVA Investors, Mr. Davis and BCM may be deemed to be members of a group, but disclaim the existence of any such group.
    The address of each of BCTG Holdings, Boxer Capital, MVA Investors, Mr. Davis and BCM for purposes of this filing is: 12860 El Camino Real, Suite 300, San Diego, CA 92130.
    Set forth on Schedule A, and incorporated herein by reference, is the (a) name, (b) residence or business address, (c) present principal occupation or employment and (d) citizenship, of each executive officer and director of each of BCTG Holdings, Boxer Capital, MVA Investors and BCM, and (e) name of any corporation or other organization in which such occupation or employment is conducted, together with the principal business and address of any such corporation or organization other than BCTG Holdings, Boxer Capital, MVA Investors or BCM.
    None of the Reporting Persons nor any of the individuals identified on Schedule A to this Schedule 13D has, during the past five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting, or mandating activities subject to, federal or state securities laws or a finding of any violation with respect to such laws.




    Item 3.
    Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended by the addition of the following:

    The disclosure set forth below in Item 4 is hereby incorporated herein.

    Item 4.
    Purpose of Transaction.

    Item 4 is hereby amended by the addition of the following:

    On October 10, 2024, Boxer Management, Boxer Capital and BCM entered into the IMA, pursuant to which Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the shares of Common Stock held by Boxer Capital and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock.

    Item 5.
    Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated to read as follows:
     
    All percentages are based on 107,176,965 shares of the Issuer’s Common Stock outstanding, which is (i) 107,144,465 shares of the Issuer’s Common Stock outstanding as of August 1, 2024 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 7, 2024, plus (ii) 32,500 shares of Common Stock subject to options to purchase shares of Common Stock, held by Mr. Davis, exercisable in the next 60 days.
    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 15,328,385 shares of Common Stock, representing 14.3% of the outstanding shares of Common Stock.
    BCTG Holdings beneficially owns 6,988,450 shares of Common Stock which represents 6.5% of the outstanding Common Stock. BCM beneficially owns 8,198,642 shares of Common Stock which represents 7.6% of the outstanding Common Stock. MVA Investors beneficially owns 108,793 shares of Common Stock which represents 0.1% of the outstanding Common Stock. Mr. Davis beneficially owns 8,339,935 shares of Common Stock which includes the shares of Common Stock beneficially owned by MVA Investors and BCM and which represents 7.8% of the outstanding Common Stock.
    (b) With respect to any rights or powers to vote, or to direct the vote of, or to dispose of, or to direct the disposition of, the Common Stock owned by the Reporting Persons:
     
    (i)
    Sole power to vote or to direct the vote:

       
         BCTG Holdings has the sole power to vote or to direct the vote of 6,988,450 shares of Common Stock. Mr. Davis has the sole power to vote or to direct the vote 32,500 shares of Common Stock underlying Issuer options exercisable within 60 days.

     
    (ii)
    Shared power to vote or to direct the vote:

       
         BCM and Mr. Davis and have shared power to vote or to direct the vote of 8,198,642 shares of Common Stock. MVA Investors and Mr. Davis have shared power to vote or direct the vote of 108,793 shares of Common Stock.

     
    (iii)
    Sole power to dispose or to direct the disposition of:

       
         BCTG Holdings has the sole power to dispose or to direct the disposition of 6,988,450 shares of Common Stock. Mr. Davis has the sole power to dispose or to direct the disposition of 32,500 shares of Common Stock underlying Issuer options exercisable within 60 days.

     
    (iv)
    Shared power to dispose or to direct the disposition of:

       
         BCM and Mr. Davis have shared power to dispose or to direct the disposition of 8,198,642 shares of Common Stock. MVA Investors and Mr. Davis have shared power to vote or direct the vote of 108,793 shares of Common Stock.




    (c) Other than as described herein in Item 4 or transactions previously reported on Form 4, the Reporting Persons have not engaged in any transactions in the Common Stock in the past 60 days.
    (d) Other than as described herein and except as may result from indirect interests of investors in Boxer Capital, BCTG Holdings, MVA Investors or BCM, no persons other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends, or proceeds of sale of such securities outlined in this report.
    (e) As described in Item 4, as of October 10, 2024, Boxer Capital ceased to beneficially own more than 5% of the outstanding shares of Common Stock.
    Item 7.
    Material to be Filed as Exhibits.

    Item 7 is hereby amended by the addition of the following:

    Exhibit No.
    Description
    Exhibit 3
     
     
    Joint Filing Agreement, dated October 15, 2024, among BCTG Holdings, Boxer Capital, MVA Investors, Mr. Davis and BCM.
     
     





    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 15, 2024

     
    BCTG HOLDINGS, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Manager
     
     
     
    BOXER CAPITAL, LLC
     
     
     
    By: Boxer Asset Management Inc.
    Its: Manager

     
     
    By:
    /s/ Paul Higgs
     
        Name:
    Paul Higgs
     
        Title:
    Director
     

     
    MVA INVESTORS, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Authorized Signatory
     

     
    AARON I. DAVIS
     
     
     
     
     
    /s/ Aaron I. Davis
     
      
    Aaron I. Davis Individually
     
         


     
    BOXER CAPITAL MANAGEMENT, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Chief Executive Officer
     

     


    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)
     In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Tango Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
    Dated: October 15, 2024.
     
    BCTG HOLDINGS, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Manager
     
     
     
    BOXER CAPITAL, LLC
     
     
     
    By: Boxer Asset Management Inc.
    Its: Manager

     
     
    By:
    /s/ Paul Higgs
     
        Name:
    Paul Higgs
     
        Title:
    Director
     
     

     
    MVA INVESTORS, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Authorized Signatory
     

     
    AARON I. DAVIS
     
     
     
     
     
    /s/ Aaron I. Davis
     
      
    Aaron I. Davis Individually
     
         


     
    BOXER CAPITAL MANAGEMENT, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Chief Executive Officer
     

     


     
    SCHEDULE A
    ADDITIONAL INFORMATION CONCERNING THE REPORTING PERSONS
    BCTG HOLDINGS, LLC
    The managers of BCTG Holdings, LLC are set forth below. The individuals’ business addresses are 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name refers to employment with BCTG Holdings, LLC.
     
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Aaron I. Davis
     
    Manager
     
    United States
    Christopher Fuglesang
     
    Manager
     
    United States
    Andrew Ellis
     
    Manager
     
    United States
    BOXER CAPITAL, LLC
    The executive officers and managers of Boxer Capital, LLC are set forth below. The individuals’ business addresses are 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name refers to employment with Boxer Capital, LLC.
     
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Boxer Asset Management Inc.
     
    Manager
     
    Bahamas
    MVA INVESTORS, LLC
    The executive officers and directors of MVA Investors, LLC are set forth below. The individuals’ business addresses are 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name refers to employment with MVA Investors, LLC.
     
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Aaron I. Davis
     
    Manager, Chief Executive Officer
     
    United States
    Christopher Fuglesang
     
    Member, President
     
    United States
             


    BOXER CAPITAL MANAGEMENT, LLC
    The executive officers and directors of Boxer Capital Management, LLC are set forth below. Each individual’s business address is 12860 El Camino Real, Suite 300, San Diego, CA 92130. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name of each person refers to employment with Boxer Capital Management, LLC. Boxer Holdings, LP, a Delaware limited partnership, is the sole member of Boxer Capital Management, LLC. Boxer Holdings GP, LLC, a Delaware limited liability company, is the general partner of Boxer Holdings, LP. Mr. Davis is the Manager of, and together with his immediate family owns all of the interests in, Boxer Holdings GP, LLC.

             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Aaron I. Davis
     
    Chief Executive Officer; Chief Investment Officer; Manager
     
    United States
    Christopher Fuglesang
     
    Senior Managing Director
     
    United States
    Michael Beauchamp
     
    Vice President of Finance
     
    United States







    Get the next $TNGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    7/15/2026$46.00Overweight
    Analyst
    6/26/2026$60.00Hold → Buy
    Jefferies
    6/8/2026Peer Perform → Outperform
    Wolfe Research
    5/15/2026$24.00Overweight → Neutral
    Piper Sandler
    5/14/2026$27.00Buy → Hold
    Jefferies
    4/3/2026$30.00Buy
    Canaccord Genuity
    4/2/2026$30.00Buy
    Canaccord Genuity
    2/23/2026$19.00Outperform
    Mizuho
    More analyst ratings

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics Appoints Robert Azelby to Board of Directors

    BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with

    6/22/26 4:05:00 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

    BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the "Offering"). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the

    6/9/26 10:49:28 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces Proposed $500 Million Public Offering

    BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the "Offering") of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock offered in the Offering under the same terms and conditions. The Offering is subject to market conditions, and there can be no assurance as to wh

    6/8/26 4:01:00 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

    4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 7:41:18 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 6:04:34 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D Crystal Adam sold $798,908 worth of shares (27,000 units at $29.59) as part of a pre-agreed trading plan and exercised 27,000 shares at a strike of $5.20 (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    7/2/26 7:23:37 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Azelby Robert was granted 5,740 shares (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    6/23/26 6:10:39 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Azelby Robert

    3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    6/23/26 6:04:06 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Tango Therapeutics with a new price target

    Analyst initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $46.00

    7/15/26 8:51:47 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Tango Therapeutics from Hold to Buy and set a new price target of $60.00

    6/26/26 8:42:49 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics upgraded by Wolfe Research

    Wolfe Research upgraded Tango Therapeutics from Peer Perform to Outperform

    6/8/26 11:47:16 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    SEC Filings

    View All

    SEC Form 8-K filed by Tango Therapeutics Inc.

    8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

    6/23/26 5:19:36 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Tango Therapeutics Inc.

    144 - Tango Therapeutics, Inc. (0001819133) (Subject)

    6/11/26 6:00:38 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tango Therapeutics Inc.

    8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

    6/10/26 5:22:21 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Appoints Robert Azelby to Board of Directors

    BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with

    6/22/26 4:05:00 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Financials

    Live finance-specific insights

    View All

    Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

    Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit  Vopimetostat combinations with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib were generally well-tolerated Data support rapid advancement of vopimetostat plus daraxonrasib combination into Phase 3 development in first-line MTAP deleted pancreatic cancer Conference call today, June 8, 2026, at 8:00am ET BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to

    6/8/26 6:59:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

    BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat

    2/18/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cance

    10/29/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/7/24 9:35:56 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    10/28/24 9:22:40 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care